Alembic Pharmaceuticals Limited (APLLTD) fair value: what the stock is really worth
As of Nov 9, 2026: fair value (intrinsic value) of Alembic Pharmaceuticals Limited stock ₹1,036, price ₹1,017, upside +1.8%, quality 56 out of 100. Rating: fairly valued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.
How to read this chart
60‑month range ₹446.68 – ₹1,216 · fair‑value band ₹559.78 – ₹1,492 · the ₹1,017 price screens below the ₹1,036 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). As of Nov 10, 2026.
Follow Alembic Pharmaceuticals in your weekly email
Every Wednesday you see whether Alembic Pharmaceuticals is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Alembic Pharmaceuticals Limited, an integrated pharmaceutical company, develops, manufactures, markets, and sells pharmaceutical products in India and internationally.
Show moreShow less
The company provides products in various therapeutic areas, such as cardiology, orthopaedics, anti-diabetic, ophthalmology, gynaecology, nephrology, gastrology, urology, dermatology, anti-infective, cold and cough, and animal health; generics formulations in oral solids, oncology oral solids and injectables, general injectables and ophthalmic products, dermatology, and oral suspension; and active pharmaceutical ingredients.
It also exports its products. Alembic Pharmaceuticals Limited was founded in 1907 and is headquartered in Vadodara, India.
Stock analysis
Alembic Pharmaceuticals Limited (APLLTD) currently trades at ₹1,017, while our model-based Fair Value estimate is ₹1,036, so the stock looks roughly fairly valued today (gap 1.8%).
Show more
Valuation
Bull case: the Multiples group reads highest at a median of ₹681.78 per share, and 2 of the 26 models we run sit above the ₹1,017 price.
Bear case: the Dividend Discount group reads lowest at ₹150.02, and 24 of the 26 models stay below the price. Data coverage for this calculation is medium.
Scenario range: ₹559.78 (bear) to ₹1,492 (bull), the price of ₹1,017 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 56/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Alembic Pharmaceuticals Limited reported revenue of ₹73.4B in FY2026 versus ₹53.1B in FY2022, a compound +8.5%/yr. Reported net income was ₹6.7B in FY2026, compounding +6.7%/yr from FY2022.
Key figures
Market cap ₹200B (≈ $2.1B) Mid · P/E ratio 23.7 · P/S ratio 2.35 · EPS (TTM) ₹42.93 · Dividend yield 1.2% · Net margin 9.9% · Return on equity 14.9% · Return on assets (EBIT) 28.1% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 55 out of 100 (low confidence).
What moves the price
The share trades at its 52-week high and 60% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −27% fair-value upside, at 2%, APLLTD screens cheaper than that median.
Fair Value models
Bear₹559.78Fair Value ₹1,036Bull₹1,492
Price ₹1,017 · Upside +1.8%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models. Based on fiscal year 2026 figures (about 7 months old). Earnings retained since then (₹19.07 per share) are deliberately not added.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Best data coverage
FCF DCF₹188.29₹304.65₹479.6779
Growth DCF₹186.24₹290.25₹438.1778
Residual Income₹252.63₹283.08₹363.2676
All 26 models by family
DCF Models
FCF DCF₹188.29₹304.65₹479.6779
Owner Earnings₹210.28₹340.53₹536.4675
5Y Revenue Exit₹298.41₹541.20₹871.5171
5Y EBITDA Exit₹412.55₹772.18₹1,22373
5Y P/E Exit₹394.90₹736.45₹1,12569
10Y Revenue Exit₹242.01₹445.26₹755.8564
10Y EBITDA Exit₹321.69₹599.33₹1,02166
10Y P/E Exit₹310.99₹575.50₹947.1762
Earnings-Based
Graham-Dodd₹233.43₹1,018₹1,39264
Lynch FV₹262.17₹374.52₹486.8861
PEG = 1.0₹262.17₹374.52₹486.8857
EPV₹300.67₹341.67₹375.9474
Dividend Discount
Gordon GGM₹86.46₹157.14₹217.9468
DDM Multi-Stage₹86.46₹142.89₹167.7167
Multiples
P/E Multiple₹566.42₹755.23₹944.0363
P/S Multiple₹437.69₹583.58₹729.4858
P/B Multiple₹772.13₹1,030₹1,28755
EV/EBIT₹456.42₹629.38₹802.3366
EV/EBITDA₹535.02₹734.18₹933.3367
EV/Revenue₹307.89₹466.60₹625.3153
Asset-Based
NCAV (Graham)₹49.86₹75.54₹94.4254
Growth DCF
Growth DCF₹186.24₹290.25₹438.1778
Rev-Margin DCF₹298.41₹533.19₹829.6471
Economic Profit
Residual Income₹252.63₹283.08₹363.2676
ROIC Compounder₹305.36₹382.01₹482.2972
Growth Earnings
Growth-Adj P/E₹446.36₹637.66₹828.9667
The fair value above starts from this blend and is adjusted for a year distorted by one-off effects.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.63/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
+10.1%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.1%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Start year 2021 (pandemic). Over 10 years: +8.9% a year
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+12.4%
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
’26
What shareholders gained per year (last 5 years), in INR ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Measured in INR: this currency has depreciated against the euro and dollar over the long run, so part of the nominal rate is currency erosion that never reaches a EUR/USD investor.
−3.6%
Earnings growth per share plus dividend.
Earnings per share, growth per year−4.8%
Dividend (yield on the price)1.2%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4.8% vs 4.8%, slowing
Profit margin 2010 to 2026 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.6% → 11%
Pace: the 5-year rate starts in 2021 (pandemic)
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+40.3%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+7.9%
Yearly sales growth analysts expect, extended to five years.
After inflation (India: IMF forecast 4.1% a year to 2030, 4.7% from 2016 to 2025) that is about +34.7% a year for the price and +3.6% for the forecasts.
Compare Alembic Pharmaceuticals Limited with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 605 stocks
Beats the industry median on 9/14 measures
Overall it ranks above its industry peers.
Valuation
Quality Score56 · Above median
Fair Value upside+1.8% · Above median
Profitability
Return on equity (12 months)14.9% · Top 25%
Return on assets7.7% · Top 25%
Net margin (12 months)9.9% · Above median
Operating margin (12 months)18.2% · Top 25%
Growth and dividend
Revenue growth (quarter YoY)37.1% · Top 25%
Dividend yield (12 months)1.2% · Below median
Balance sheet
Debt / equity0.02× · Below median
Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Alembic Pharmaceuticals Limited (APLLTD) overvalued or undervalued?
As of Nov 10, 2026, our model estimates a fair value of ₹1,036 versus a price of ₹1,017, about +2% upside (fairly valued).
What is the fair value of APLLTD?
Our model-based fair value for Alembic Pharmaceuticals Limited is ₹1,036 (as of Nov 10, 2026), built from audited fundamentals. The current price: ₹1,017.
What is the quality score of APLLTD?
Alembic Pharmaceuticals Limited has a Quality Score of 56/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Alembic Pharmaceuticals Limited (APLLTD)?
Our model-based price target is the fair value of ₹1,036 (as of Nov 10, 2026) from 26 valuation models. Cautious scenario ₹559.78, optimistic scenario ₹1,492. It is a calculation from audited fundamentals, not an analyst target.
What is the Alembic Pharmaceuticals Limited stock forecast for 2026?
Our models put fair value at ₹1,036, about +2% upside versus a price of ₹1,017 (fairly valued). Cautious scenario ₹559.78, optimistic scenario ₹1,492. The calculation is refreshed regularly with new filings.
What is the revenue of Alembic Pharmaceuticals Limited (APLLTD)?
Alembic Pharmaceuticals Limited reported trailing-twelve-month revenue of about ₹84.9B (latest available figure, as of Nov 10, 2026).
Does Alembic Pharmaceuticals Limited pay a dividend?
Alembic Pharmaceuticals Limited currently shows a dividend yield of 1.18% relative to its recent price (as of Nov 10, 2026).
How much is the dividend of Alembic Pharmaceuticals Limited (APLLTD) and when is the ex-dividend date?
Alembic Pharmaceuticals Limited pays a dividend of ₹12.00 per share a year, a dividend yield of 1.2%. The last ex-dividend date was Jul 29, 2026. A dividend has been paid every year since at least 2012. The payout ratio is 28.0% of earnings. Free cash flow covers the dividend 1.11 times. Our assessment: Well covered. A low payout and the dividend is fully funded by free cash flow, a comfortable, sustainable dividend.
What growth is priced into Alembic Pharmaceuticals Limited (APLLTD)?
For today's price to be fair in a discounted-cash-flow model, Alembic Pharmaceuticals Limited would have to grow free cash flow by +40.3 % per year for five years (discount rate 10.9 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew +6.4 % per year. As of Nov 10, 2026.
What discount rate (WACC) does the fair value of APLLTD use?
Our models discount Alembic Pharmaceuticals Limited at 10.9 %: a base by market capitalisation (mid), damped by beta 0.34, country premium for India. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Alembic Pharmaceuticals Limited that is +40.3 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (10.9 %) and the same formula as our fair value.
How much growth has Alembic Pharmaceuticals Limited (APLLTD) delivered so far?
Over the past 5 years revenue at Alembic Pharmaceuticals Limited grew +6.4 % a year. The price currently implies free-cash-flow growth of +40.3 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Alembic Pharmaceuticals Limited (APLLTD) growing?
The median revenue growth in the sector is +5.9 % a year. That is the yardstick for the growth priced into Alembic Pharmaceuticals Limited (+40.3 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Alembic Pharmaceuticals Limited (APLLTD)?
The free-cash-flow yield on the price is 1.30 %: that much free cash flow Alembic Pharmaceuticals Limited produces per unit of market value. When it exceeds the discount rate of our models (10.9 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Alembic Pharmaceuticals Limited (APLLTD)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Alembic Pharmaceuticals Limited it is ₹1,036 per share (as of Nov 10, 2026), against a price of ₹1,017. It is the blended result of 26 valuation models in 8 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings).
Is Alembic Pharmaceuticals Limited stock overvalued or undervalued in 2026?
As of Nov 10, 2026, APLLTD trades below its calculated fair value: price ₹1,017, fair value ₹1,036, a gap of about +2% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of APLLTD?
No. The price is what the market pays today (₹1,017); the fair value is what the company's own numbers justify (₹1,036). For Alembic Pharmaceuticals Limited the two are ₹18.60 per share apart. That gap is exactly why we show both numbers side by side.
How much is Alembic Pharmaceuticals Limited worth?
The market values Alembic Pharmaceuticals Limited at about ₹200B (market capitalisation, as of Nov 10, 2026). Per share that is ₹1,017; our models calculate a fair value of ₹1,036 per share.
What do the bullish and bearish scenarios say about APLLTD?
Our models span a range for Alembic Pharmaceuticals Limited: cautious scenario ₹559.78, base ₹1,036, optimistic ₹1,492 per share (as of Nov 10, 2026, price ₹1,017). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of APLLTD?
Alembic Pharmaceuticals Limited trades at a price-to-earnings ratio of 23.7 (as of Nov 10, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of ₹1,036 is built from several models across several years. Median P/E at fiscal year-end, 10 fiscal years (2017 to 2026), reported earnings: 26.5. Other multiples: P/B 3.5, P/S 2.4, EV/EBITDA 14.1.
How solid is the balance sheet of Alembic Pharmaceuticals Limited (APLLTD)?
Balance-sheet figures for Alembic Pharmaceuticals Limited (as of Nov 10, 2026): return on equity 14.9%, debt of 0.02 per unit of equity. They feed the Quality Score of 56/100, which measures business quality independently of the share price.
How far is APLLTD from its 52-week high?
Alembic Pharmaceuticals Limited trades at ₹1,017, at its 52-week high of ₹1,017 and 60% above the low of ₹637.08 (as of Nov 9, 2026). Distance from the high says nothing about value: that is what the fair value of ₹1,036 is for.
Which stocks are comparable to Alembic Pharmaceuticals Limited?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Galderma Group, Teva Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Alembic Pharmaceuticals Limited stock attractive at the current price?
The data as of Nov 10, 2026: price ₹1,017, calculated fair value ₹1,036 (+2%), Quality Score 56/100, from 26 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of APLLTD calculated?
We run Alembic Pharmaceuticals Limited through 26 models from 8 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Asset-Based, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of ₹1,036 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Alembic Pharmaceuticals Limited currently trades 2% below its own fair value, and the market average says nothing about that. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Alembic Pharmaceuticals Limited (APLLTD)?
The closing price on Nov 9, 2026 was ₹1,017. Our model-based fair value is ₹1,036, about +2% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Alembic Pharmaceuticals Limited right now?
The model range is unusually wide (₹559.78 to ₹1,492). The outcome hinges heavily on assumptions, so read the point estimate with caution. The price sits close to our fair value, market and models broadly agree here, little valuation tension.
Where does the earnings growth of Alembic Pharmaceuticals Limited (APLLTD) come from?
Earnings per share at Alembic Pharmaceuticals Limited grew +2.8 % a year from 2015 to 2026. Broken into its drivers: revenue per share +9.9 %, EBIT margin −4.4 %, tax rate +2.0 %, residual (interest, one-offs) −4.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Alembic Pharmaceuticals Limited
How large is the market capitalisation of Alembic Pharmaceuticals Limited (APLLTD)?
The market capitalisation of Alembic Pharmaceuticals Limited is ₹200B (≈ $2.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Alembic Pharmaceuticals Limited (APLLTD)?
The price-to-sales ratio of Alembic Pharmaceuticals Limited is 2.35 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Alembic Pharmaceuticals Limited (APLLTD)?
Earnings per share at Alembic Pharmaceuticals Limited are ₹42.93 (price ÷ EPS = P/E 23.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Alembic Pharmaceuticals Limited (APLLTD)?
The dividend yield of Alembic Pharmaceuticals Limited is 1.2% (payout 28.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Alembic Pharmaceuticals Limited (APLLTD)?
The net margin of Alembic Pharmaceuticals Limited is 9.9% (last twelve months). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Alembic Pharmaceuticals Limited (APLLTD)?
The return on equity (ROE) of Alembic Pharmaceuticals Limited is 14.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Alembic Pharmaceuticals Limited (APLLTD)?
On an EBIT basis the return on assets of Alembic Pharmaceuticals Limited is 28.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Alembic Pharmaceuticals Limited (APLLTD)?
The operating margin of Alembic Pharmaceuticals Limited is 18.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Alembic Pharmaceuticals Limited (APLLTD)?
Revenue at Alembic Pharmaceuticals Limited is growing +37.1% versus a year earlier (3y avg +9.1%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Alembic Pharmaceuticals Limited (APLLTD)?
Earnings per share at Alembic Pharmaceuticals Limited are growing +81.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Alembic Pharmaceuticals Limited (APLLTD) carry?
The net debt of Alembic Pharmaceuticals Limited is ₹12.3B (fiscal year 2026, ≈ 4.7 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Alembic Pharmaceuticals Limited in the live analysis
One click puts Alembic Pharmaceuticals Limited on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 10, 2026